Pharmac is asking pharmaceutical suppliers about the potential of securing oestradiol gel as an option for Kiwis following global challenges to supply crucial hormone replacement therapy patches.
Oestradiol is used by 85,000 people each year for the treatment of a range of conditions including, menopause, osteoporosis, and gender affirming health care.
Demand for hormone replacement therapy (HRT) oestradiol patches has more than doubled in the last three years, prompting calls for the use of new treatment such as oestradiol gel to be funded in New Zealand.
Women continue to face shortages of hormone replacement therapy patches despite the number being brought into the country doubling in recent years. (Source: 1News)
Pharmac's Chief Medical Officer Dr David Hughes said the organisation has now issued a request to suppliers for proposals to bid for the supply of oestradiol gel in New Zealand.
"Our clinical advisors have told us that funding another oestradiol product would be useful because demand is increasing and we are continuing to experience global supply issues for oestradiol patches.
"We know that some people would use the gel if it's funded, and this could relieve some of the stress on the supply of patches.
"We want to make sure people get the treatment they need, and which can be funded from Pharmac’s fixed budget, so we’re keen to hear from suppliers about what they can offer," said Hughes.
Global demand over recent years for oestradiol patches has increased substantially — driven by increasing awareness of the benefits of oestradiol in managing menopausal symptoms.
Menopause specialist Dr Linda Dear said a gel would be a "much-needed alternative".
Women continue to face shortages of hormone replacement therapy patches despite the number being brought into the country doubling in recent years. (Source: 1News)
"It's wonderful to hear that another step is being taken towards giving perimenopausal and menopausal New Zealanders fully funded access to oestradiol (estrogen) gels," she said.
"Having gels as an alternative will ease the pressure of the supply issue which has had an impact on New Zealanders using the treatments, pharmacists, and prescribing doctors alike. My hope is that we don’t have to wait too much longer to access this important therapy."
Hughes said an evaluation committee would meet to consider any bids received once the request for proposals window closes and wouid also seek advice from clinical advisors.
SHARE ME